Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of fulzerasib with itraconazole or dextromethorphan
NCT05699993Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fulzerasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and solid tumor (2 arms), sponsored by Innovent Biologics. Primary endpoints: Maximum Concentration at 10 days and Area Under the Curve to Infinity at 10 days. Started Mar 2023; status: completed.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05699993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699993.